VJHemOnc is committed to improving our service to you

IMW 2019 | MGUS: predicting the risk of progression

VJHemOnc is committed to improving our service to you

Tarek H Mouhieddine

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, describes the rationale for the improved identification of high-risk patients who may be appropriate for novel clinical interventions to prevent progression or eradicate premalignant clones prior to the development of overt multiple myeloma (MM) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter